Navigation Links
One in Four Surveyed EU5 Physicians Has Been Required to Change a Prescription for Some or Most of Their HIV Patients in the Past Twelve Months, Primarily to Reduce Costs
Date:6/18/2013

ir HIV patients by the end of 2014.

The report also finds that the serious public health threat posed by ongoing transmission of HIV and pushback from well-organized and influential patient advocates will constrain payers' ability to mandate use of cheaper multi-pill regimens. However, interviewed payers do believe that declining budgets and increasing numbers of patients requiring treatment will drive physicians to "break" coformulated, single pill products into multi-pill regimens to some extent in order to capture generic savings and meet their growing clinical burdens.

"Historically, new HIV agents have not been subjected to cost-effectiveness analyses owing to the serious public health threat posed by HIV infections and limited availability of effective drugs," said Decision Resources Analyst Seamus Levine-Wilkinson, Ph.D. "However, the pressure to reduce costs while providing treatment to more patients will drive increasingly stringent payer reviews in which competitive pricing and regionally tailored dossiers will play critical roles in securing formulary placement. Payers in the United Kingdom, in particular, warn that companies that resist price negotiations are being unrealistic and run the risk of losing out to more amenable drug developers."

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please
'/>"/>

SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Rising Drug Resistance is Driving Early-Line Use of Powerful Antibiotics Such as Carbapenems for Gram-Negative Infections, According to Surveyed EU5 Physicians
2. For Second- and Subsequent-Line Metastatic Castrate-Resistant Prostate Cancer, Surveyed Oncologists Indicate that Improved Symptom Control and Quality of Life is one of the Greatest Unmet Needs
3. For Chronic Obstructive Pulmonary Disease, Surveyed Pulmonologists Indicate That Improved Effect on Quality of Life is One of the Greatest Unmet Needs
4. The Majority of Surveyed Gastroenterologists in the EU5 Identify Remicade as Their Most Preferred Biologic for the Treatment of Ulcerative Colitis
5. For Treating Clostridium difficile Infections, Surveyed Infectious Disease Specialists Agree That Effect on Recurrence Rate is One of the Drug Attributes that Most Influences Their Prescribing Decisions
6. Surveyed U.S. Pulmonologists Expect to Treat Nearly 50 Percent of Their Severe, Refractory Asthma Patients With a Biologic or Biosimilar Version of Xolair By the End of 2018
7. Surveyed U.S. Neurologists Would Prescribe Biogen Idecs Tecfidera to 20 Percent of Their Patients with Relapsing-Remitting Multiple Sclerosis (RR-MS)
8. Surveyed U.S. Physicians Indicate That Xarelto and Apixaban Will Benefit From the Lack of Use of a Fast-Acting Injectable Anticoagulant in the Treatment and Secondary Prophylaxis of Deep Vein Thrombosis/Pulmonary Embolism
9. Despite the Recent Availability of Xtandi, Zytiga Continues to Dominate the Second-Line Metastatic Castrate-Resistant Prostate Cancer Setting, According to Surveyed U.S. Oncologists and Urologists
10. Surveyed U.S. and European Neurologists Agree that a Therapys Effect on Physical Disability is the Most Important Attribute Influencing Prescribing Decisions in Secondary-Progressive Multiple Sclerosis
11. According to Surveyed Oncologists in the EU5, Zytiga Has Heavily Penetrated Second-Line Treatment of Metastatic Castrate-Resistant Prostate Cancer (mCRPC) and is Displacing Jevtana to Later-Line mCRPC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... -- Children aren,t the only segment of our ... disease. The Centers for Disease Control and Prevention ... many adults are not following this advice. ... and the American Lung Association in partnership with ... disease, to talk with their health care provider ...
(Date:8/20/2014)... , Aug. 20, 2014 ... report is available in its catalogue: ... for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, ... http://www.reportlinker.com/p0652514/Wireless-Opportunities-in-Healthcare-The-Market-for-Bluetooth-RFID-Zigbee-UWB-WWAN-WMAN-WLAN-and-other-technologies.html Kalorama Information,s ... Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN ...
(Date:8/20/2014)... 2014  Decision Resources Group finds that ... device market will expand through 2023 as ... fibrillation (AF). The increasing acceptance of ablation ... will spur adoption of premium-priced products designed ... loop diagnostic catheters, cryoablation catheters and contact ...
Breaking Medicine Technology:American Lung Association Urges Adults with Lung Disease to Consult their Health Care Provider to Stay Current on Vaccinations 2American Lung Association Urges Adults with Lung Disease to Consult their Health Care Provider to Stay Current on Vaccinations 3Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 2Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 3Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 4Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 5Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 6Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 7Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 8Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 9Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 10Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 11Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 12Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 13Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 14Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 15Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 16Electrophysiology Mapping and Ablation Device Market in Japan to Reach $1.1 Billion by 2023 2Electrophysiology Mapping and Ablation Device Market in Japan to Reach $1.1 Billion by 2023 3
... April 18, 2011 Regeneron Pharmaceuticals, Inc. (Nasdaq: ... and Drug Administration (FDA) has accepted for review the ... the treatment of the neovascular form of age-related macular ... request for priority review of its BLA.  A Priority ...
... PDL BioPharma, Inc. (PDL) (NASDAQ: ... meeting of stockholders on Wednesday, June 22, 2011 at 10:00 a.m. ... The meeting will take place at the Hyatt Regency Hotel in ... PDL pioneered the humanization of monoclonal antibodies and, ...
Cached Medicine Technology:FDA Grants Priority Review for VEGF Trap-Eye for the Treatment of Wet Age-Related Macular Degeneration 2FDA Grants Priority Review for VEGF Trap-Eye for the Treatment of Wet Age-Related Macular Degeneration 3
(Date:8/20/2014)... In less than a week the airwaves ... to fight muscle related disease. Helping the huge telethon ... brands through their cause-related marketing heft. With their help ... nearly $60 million. , But for small self-serve business ... cause-related marketing remains decidedly local and, although the money ...
(Date:8/20/2014)... 21, 2014 Recently, UWDress.com, the distinguished ... selection of birthday party dresses for girls . ... are well-designed and exquisitely handmade by experienced specialists. Now, ... percent off. , The company’s new items come in ... short knee length frocks, long elegant backless gowns and ...
(Date:8/20/2014)... Jacksonville, FL (PRWEB) August 20, 2014 ... Continuing Education Standards (IBCCES) , an organization recognizing ... area of autism, has announced that with a ... in working with people on the Autism Spectrum ... commitment to providing quality care. This, in turn, ...
(Date:8/20/2014)... 2014 (HealthDay News) -- A group representing U.S. obstetricians ... flu shot. According to the American College of ... years have upheld the safety and effectiveness of flu ... infectious and can be particularly dangerous to pregnant women, ... complications," Dr. Laura Riley, chair of the college,s Immunization ...
(Date:8/20/2014)... the immune system is defective in people suffering from irritable ... ongoing issues with pain. , The research the first ... to explain why some painkillers may not offer satisfactory relief ... 10% of the community. There are different forms of ... often has the greatest impact on sufferers, quality of life. ...
Breaking Medicine News(10 mins):Health News:On Eve of Big Telethon, Froyo Businesses Participate but Also Go Their Own -- Local Way 2Health News:On Eve of Big Telethon, Froyo Businesses Participate but Also Go Their Own -- Local Way 3Health News:Cheap Birthday Party Dresses for Girls Now Available at UWDress.com 2Health News:National Autism Certificate Credentialing Board IBCCES Increases Job Placement Opportunities for Those Dedicated to Working Within the Autism Spectrum 2Health News:National Autism Certificate Credentialing Board IBCCES Increases Job Placement Opportunities for Those Dedicated to Working Within the Autism Spectrum 3Health News:All Pregnant Women Need Flu Shot: Ob/Gyn Group 2Health News:Pain treatments less effective for those with irritable bowel 2
... leader in soft-cloth nasal CPAP masks, announces the new Zzzephyr ... comfortably over the patient,s nose. The lightweight seal reduces air ... Obstructive Sleep Apnea patients. , The SleepWeaver ADVANCE with Zzzephyr ... at the Medtrade Fall Show in Atlanta, Georgia, October 12 ...
... Calif., Oct. 26 Ingenuity Systems, the leading provider ... it has developed a new gene expression workflow with ... and the Applied Biosystems SOLiD(TM) System and TaqMan® Gene ... for researchers to analyze and understand the transcriptome of ...
... particularly younger women, experienced larger improvements in hospital mortality ... study published in the Oct. 26, 2009 issue of ... decade several studies showed that younger women, but not ... hospital after MI than age-matched men. A team of ...
... The topical application ... and absorption throughout the surface of the skin and scalp. A new line of naturally ... for a variety of topical conditions affecting the skin, scalp and feet. , ... Schenectady, NY (PRWEB) October 26, 2009 -- ...
... ... announce it has been honored with the BayCare Quality Award for the team,s project ... patient successes including follow through on outpatient office visits, 30-day readmission rates, and A1c ... ...
... Arena Pharmaceuticals, Inc. (Nasdaq: ARNA ) ... modification and Lorcaserin for Overweight and Obesity Management) ... weight loss, improved markers of cardiovascular risk and ... or suicidal ideation. Additional subgroup analyses showed that ...
Cached Medicine News:Health News:Circadiance Launches NEW Zzzephyr Seal(TM) for Its SleepWeaver(TM) ADVANCE Mask - Now Available in Three Colors 2Health News:Ingenuity Systems Enhances Workflow for Experimental Transcriptome Analysis in Single Cells 2Health News:Survival after heart attack improves in younger women 2Health News:Caffeinated Cayenne Pepper Body Sprays Relieve Common Skin and Scalp Problems 2Health News:Caffeinated Cayenne Pepper Body Sprays Relieve Common Skin and Scalp Problems 3Health News:IN Compass Health's Hospitalist Team at Morton Plant wins first BayCare Quality Award 2Health News:IN Compass Health's Hospitalist Team at Morton Plant wins first BayCare Quality Award 3Health News:Positive Data from Arena Pharmaceuticals' Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Glycemic Parameters and was not Associated with Depression or Suicidal Ideation 2Health News:Positive Data from Arena Pharmaceuticals' Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Glycemic Parameters and was not Associated with Depression or Suicidal Ideation 3Health News:Positive Data from Arena Pharmaceuticals' Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Glycemic Parameters and was not Associated with Depression or Suicidal Ideation 4Health News:Positive Data from Arena Pharmaceuticals' Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Glycemic Parameters and was not Associated with Depression or Suicidal Ideation 5Health News:Positive Data from Arena Pharmaceuticals' Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Glycemic Parameters and was not Associated with Depression or Suicidal Ideation 6Health News:Positive Data from Arena Pharmaceuticals' Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Glycemic Parameters and was not Associated with Depression or Suicidal Ideation 7Health News:Positive Data from Arena Pharmaceuticals' Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Glycemic Parameters and was not Associated with Depression or Suicidal Ideation 8
MBP's equivalent to the "Universal Yellow" tip, this 200 ul tip utilizes a MicroPoint design for accurate sample handling. 10 L Ref. mark....
... easy way to order tips. Each box contains ... D10mL, which contains 200 tips (4 bags of ... Packs of 200 tips per pack. Bulk Packs ... easily be opened for quick access to Gilsons ...
10 L, Bulk Recommended for 2, 5, 10 L pipettes....
... Finntips have been designed to optimize the ... of our tip products is widely recognized ... range has been extended over the years ... standard and special tips including filter tips, ...
Medicine Products: